MME and hypertensive disorder: LCZ696, an angiotensin (AT1) receptor blocker‐neprilysin inhibitor (ARNi), in clinical studies showed a higher efficacy in hypertension management (Gu et al., 2010; Minguet, Sutton, Ferrero, Gomez, & Bramlage, 2015).